Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Startseite
  2. Aktien
  3. Dänemark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. News
  7. Andere Sprachen
    LUN   DK0061804697

LUNDBECK

(LUN)
  Bericht
Realtime-Estimate Cboe Europe  -  16:54 26.09.2022
22.88 DKK   -3.30%
13.09.Otsuka und Lundbeck geben bekannt, dass die US-Arzneimittelbehörde FDA den Antrag auf ein neues Medikament für Aripiprazol, eine 2-monatige, gebrauchsfertige, langwirksame Injektionslösung zur Behandlung von Schizophrenie und Bipolar-I-Störung bei Erwachsenen, angenommen hat
CI
17.08.H. Lundbeck A/S meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2022
CI
17.08.H. Lundbeck A/S gibt Ergebnisprognose für das Geschäftsjahr 2022 ab
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über LUNDBECK
13.09.Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazo..
17.08.TRANSCRIPT : H. Lundbeck A/S, Q2 2022 Earnings Call, Aug 17, 2022
17.08.Lundbeck's sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the..
17.08.H. Lundbeck A/S Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
17.08.H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022
09.08.Lundbeck raises financial guidance range for the full year 2022
09.08.H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022
26.07.LUNDBECK : Conducting largest study ever to observe early-stage multiple system atrophy
13.07.Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S made b..
12.07.Transactions with shares and linked securities in H. Lundbeck A/S made by executives an..
27.06.POINT SUR LES FORTES VARIATIONS DU J : Prosus s'éloigne de Tencent
27.06.TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
27.06.CORRECTION ( : Markets-Morning UPDATE1:)
27.06.Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation ..
27.06.H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agi..
20.06.Otsuka's European Unit Gets Clearance to Market Schizophrenia Drug
17.06.European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectab..
16.06.Results from the DELIVER study with Vyepti® has been published in a top-ranking medical..
16.06.H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti
15.06.L'agenda di oggi
14.06.H. LUNDBECK A/S(CPSE : HLUN A) added to OMX Nordic All-Share Index
10.06.H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
10.06.H. LUNDBECK A/S(CPSE : HLUN B) added to OMX Nordic All-Share Index
10.06.H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
09.06.H. LUNDBECK A/S(CPSE : LUN) dropped from OMX Nordic All-Share Index
08.06.Lundbeck Extraordinary General Meeting on June 8, 2022 at the company's registered offi..
08.06.TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
23.05.Lundbeck publishes Listing Document relating to the new share structure
20.05.Lundbeck publishes Listing Document relating to the new share structure
17.05.Lundbeck A/S - Notice of Extraordinary General Meeting
16.05.Notice of Extraordinary General Meeting
11.05.TRANSCRIPT : H. Lundbeck A/S, Q1 2022 Earnings Call, May 11, 2022
11.05.Focus on strategic brands continues to ensure solid operational performance in Q1 2022
11.05.H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
11.05.H. Lundbeck A/S Provides Earnings Guidance for the Year 2022
20.04.H LUNDBECK A/S : Lundbeck making strides in the field of digital biomarkers
11.04.Lundbeck's Major Depressive Disorder Therapy Shows Significant Benefits in Global Trial
11.04.Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine ..
11.04.H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the ..
08.04.Joerg Hornstein to join Lundbeck as Chief Financial Officer and Head of Corporate Funct..
08.04.H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management
08.04.H. Lundbeck A/S Appoints Joergornstein as Chief Financial Officer
02.04.Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI
30.03.Sun Pharma to Introduce Its Version of Vortioxetine in India Under an Exclusive Patent ..
29.03.H LUNDBECK A/S : Women's Mental Health Teleconsultations in Pakistan
23.03.Lundbeck held its Annual General Meeting on 23 March 2022 at the company's registered o..
23.03.H. Lundbeck A/S Announces Appointment of Employee Representatives to the Board of Direc..
23.03.H. Lundbeck A/S Announces Dividend for the Year 2021
23.03.TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
03.03.Drugmakers, device companies say sanctions may hinder medical supplies to Russia
03.03.Fabricantes de medicamentos y dispositivos médicos temen que las sanciones dificulten e..
01.03.H. Lundbeck A/S - Notice of Annual General Meeting
14.02.H. Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S mad..
14.02.BOLSA DE MADRID : El ruido de las botas
14.02.Bruits de botte
14.02.AVIS D'ANALYSTES DU JOUR : Renault, EDF, Delivery Hero, Legrand, Komax, Swatch, Aveva, AMG..
10.02.H. Lundbeck A/S - Lundbeck Annual Report 2021
10.02.H. Lundbeck A/S - Strong operational performance with continued solid growth from strat..
09.02.Transactions with shares and linked securities in H. Lundbeck A/S made by executives an..
09.02.TRANSCRIPT : H. Lundbeck A/S, 2021 Earnings Call, Feb 09, 2022
09.02.Lundbeck Plans To Split Shares Into Two Classes
09.02.Lundbeck Annual Report 2021
09.02.H. Lundbeck A/S Reports Earnings Results for the Full Year Ended December 31, 2021
09.02.Strong operational performance with continued solid growth from strategic brands in Q4 ..
09.02.H. Lundbeck A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
09.02.H. Lundbeck A/S Proposes Dividend for the Year 2021
09.02.H. Lundbeck A/S Provides Earnings Guidance for Year 2022
09.02.Lundbeck proposes a new share structure with A-shares and B-shares to increase financia..
09.02.H LUNDBECK A/S : Remuneration report 2021
25.01.H. Lundbeck A/S - Vyepti approved by the EU Commission for the preventive treatment of ..
25.01.Lundbeck's Preventive Migraine Drug Wins EU Approval
24.01.Vyepti (eptinezumab) approved by the EU Commission for the preventive treatment of migr..
24.01.EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine..
24.01.H LUNDBECK A/S : The hunt for a groundbreaking biomarker test for Parkinson's disease cont..
12.01.H LUNDBECK A/S : Greening Lundbeck
06.01.Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXU..
2021Lundbeck appoints Dr. Rupert Sandbrink as Head of Clinical Development
2021H. Lundbeck A/S Appoints Rupert Sandbrink as Head of Clinical Development
2021Lundbeck announces changes to Executive Management
2021Lundbeck's CFO To Step Down
2021Lundbeck Announces Changes to Executive Management
2021Lundbeck Names New Chief Commercial Officer
2021Lundbeck announces changes to Executive Management
2021H. Lundbeck A/S Announces Management Changes
2021H LUNDBECK A/S : From Drughunters winner to neuropsychologist
2021OPINIONES DE LOS ANALISTAS DEL DÍA : Apple, Clariant, Deliveroo, Siemens, Juste Eat, NEL, ..
2021Pluie de données avant la dinde
2021AVIS D'ANALYSTES DU JOUR : OVH, McPhy, Bic, Ipsen, NEL, Vifor, UCB, SMA Solar...
2021Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migra..
2021Lundbeck Launches Mid-Stage Study For Migraine Prevention Treatment
2021Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migr..
2021Lundbeck Announces Start of a Phase II Clinical Study to Assess Lu AG09222 for Migraine..
2021Lundbeck's Migraine Treatment Lands Positive Opinion From European Medicines Agency
2021Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migra..
2021H. Lundbeck A/S's Vyepti Recommends for Approval in the EU by CHMP for the Preventive T..
2021TRANSCRIPT : H. Lundbeck A/S, Q3 2021 Earnings Call, Nov 10, 2021
2021Lundbeck Affirms Lower Revenue Forecast For FY21
2021Lundbeck continues solid operational performance with strong growth from strategic bran..
2021H. Lundbeck A/S Provides Earnings Guidance for 2021
2021H. Lundbeck A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
Anstehende Termine für LUNDBECK